Research Article

Wubeizi Ointment Suppresses Keloid Formation through Modulation of the mTOR Pathway

Zhiming Tang,1,2 Yi Cao,3 Jicun Ding,4 Xiaoxiang Zhai,5 Mengqing Jing,2 Mengmeng Wang,2 and Lu Lu2

1The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
2Department of Dermatology, Xuzhou Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Xuzhou, China
3Department of Dermatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
4Department of Burns and Plastic Surgery, Xuzhou Central Hospital, Xuzhou, China
5Department of Dermatology, Shanghai Seventh People’s Hospital, Shanghai, China

Correspondence should be addressed to Xiaoxiang Zhai; 17740385@qq.com

Received 12 June 2020; Revised 13 August 2020; Accepted 16 September 2020; Published 30 September 2020

Academic Editor: Davinder Parsad

Copyright © 2020 Zhiming Tang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Wubeizi (Rhus chinensis Mill.) ointment has been shown as an effective treatment for keloids. However, the protective mechanisms of Wubeizi ointment are not fully understood. The mammalian target of rapamycin (mTOR) has been demonstrated to be associated with keloid pathogenesis. In the present study, we investigated if Wubeizi ointment suppressed keloid formation through the modulation of key molecules of the rapamycin (mTOR) pathway including phosphatase and tensin homolog (PTEN), phosphatidylinositol 3-kinase (PI3K), and protein kinase B (Akt).

Methods. A keloid mouse model and human keloid-derived fibroblasts were developed and treated with Galla chinensis. Immunohistochemistry, western blot, and reverse transcription-PCR were used to detect PI3K, PTEN, Akt, and mTOR in keloid tissues and keloid fibroblasts. The apoptosis and proliferation rate of keloid fibroblasts was, respectively, analyzed by flow cytometry according to the MTT assay. Statistical analysis was done using SPSS version 20.0. For two variable comparisons, a two independent samples t-test was used. For multiple variable comparisons, data were analyzed by one-way analysis of variance (ANOVA) followed by pairwise q-tests.

Results. Our in vivo and in vitro studies showed that Wubeizi ointment suppressed keloid formation through inhibition of fibroblast proliferation and promotion of fibroblast apoptosis. The underlying basis involves downregulation of p-Akt and p-mTOR as well as upregulation of PTEN. Conclusion. These findings may contribute to a better understanding of the mechanisms of Wubeizi ointment for treating keloids.

1. Introduction

Keloids are formed because of abnormal overgrowth of scar tissue during the healing of skin wounds and are characterized by the proliferation of dermal fibroblast and the aberrant accumulation of extracellular matrix (type I and III collagens, mucins, and glycosaminoglycans [1]. Wubeizi ointment has been shown as an effective treatment for keloids [1]. Our previous studies have demonstrated that Wubeizi ointment prevents the proliferation of the keloid-derived fibroblasts in a time- and dose-dependent manner [1]. In addition, Wubeizi ointment downregulated the expression of type I and III procollagen in keloid fibroblast and induced an S-phase arrest of keloid fibroblast [1, 2]. However, the mechanisms underlying the inhibitory effect of Wubeizi ointment on keloid formation are not fully understood.

mTOR is a serine/threonine kinase which plays an important role in the regulation of metabolic processes and translation rates. mTOR as a regulator of collagen expression and inhibition of mTOR reduced extracellular matrix deposition. Tissue extracts obtained from keloid scar showed an increase in the expression of mTOR, p70KDa S6 kinase, and their activated forms, suggesting an activation of mTOR in keloid scars [3]. The expression of transforming growth factor-β (TGF-β1), PI3K, Akt, and mTOR was significantly increased in pathological scar fibroblasts than in normal skin
tissue or fibroblasts [4]. In addition, application of rapamycin to monoculture keloid fibroblasts could downregulate the expression of cytoplasmic proliferating cell nuclear antigen (PCNA), cyclin D1, fibronectin, collagen, and alpha-smooth muscle actin (alpha-SMA) in a time- and dose-dependent manner, suggesting the antiproliferative effect of rapamycin in the treatment of keloid scars [4]. Therefore, we hypothesized the possibility that Wubeizi ointment could act via the mTOR signaling pathway to inhibit the formation of keloid scar.

In the present study, we investigated the effect of Wubeizi ointment on key molecules of the mTOR pathway including PTEN, PI3K, and Akt. The results may contribute to a better understanding of the protective effect of Wubeizi ointment against keloid pathogenesis.

2. Material and Methods

2.1. Drug Preparation. The formula of Wubeizi ointment includes Chinese herbs Salvia miltiorrhiza, Clematis, black vinegar, Galla Chinensis, Cortex Lycii, and alum. It was prepared as described previously [1]. Briefly, the 7 ingredients were extracted first with water. After concentrating and cooling in a rotary evaporator, ethanol was slowly added, and the solution was stirred. The medicinal solution was refrigerated for 24–48 hours and filtered to obtain the Wubeizi medicinal solution. The concentration of the Wubeizi medicinal solution was adjusted to 50 mg/ml and 30 mg/ml to obtain a concentration of 5% and 3% Wubeizi medicinal solution, respectively, and stored at −20°C for future use. The Wubeizi ointment cream was prepared as follows: 50 g of white petroleum jelly, 20 g of cetyl alcohol, 20 g of stearyl alcohol, 100 g of stearic acid, 75 g of glycercyl monostearate, and 20 g of lanolin were mixed and heated to maintain a temperature of 80°C; 10 g of borneol, Nipal 1 g of gold ethyl ester, 8 g of triethanolamine, 5 g of Tween-80, 1 g of methyl paraben, 50 g of glycerol, and add 100 mL of purified water were added, heated to dissolve and maintained the temperature at 80°C, and slowly added to the oil phase with continuous stirring till it emulsified to form a mixture. Then, 19 mL of Wubeizi medicinal solution (3% or 5%) was added and stirred to room temperature to obtain the Wubeizi ointment cream of the corresponding concentration.

2.2. Specimen Source. The keloid scar tissues were obtained from the Department of Dermatology of Xuzhou Hospital affiliated to Nanjing University of Traditional Chinese Medicine (Jiangsu, China). The tissues were taken from the anterior part of chest after surgical resection for treatment, from 18 Chinese patients (8 males and 10 females with an average age of 22.8 ± 3.2, average course of disease of 2.1 ± 0.8 years). The normal skin tissue was resected near the keloid scar tissue.

2.3. Animal Models. Eighteen nude mice were purchased from the animal facility of Xuzhou Medical University. They were housed under conditions of constant temperature and humidity and with a 12 h light–12 h dark cycle. Keloid models were generated as described previously [5]. Briefly, the mice were anesthetized with an intraperitoneal injection of 0.1% pentobarbital sodium at 0.1 ml/10 g of body weight. When the mice were completely unconscious, human keloid scar fragments (8 mm × 5 mm × 5 mm) with epidermal and dermal tissue were implanted into the back of the nude mice like a full thickness skin graft. The animal models were ready for use after 14 days of implantation since by this time peripheral vascularization followed by anastomosis would have been completed [6]. The animals were then divided into three groups; i.e., control group, 3% Wubeizi ointment-treated group, and 5% Wubeizi ointment-treated group (n = 6 for each group). For the Wubeizi ointment-treated group, the corresponding concentration of Wubeizi ointment was applied to the skin (0.5 g/10 mm², 3 times a day). For the control group, only the matrix of Wubeizi ointment was applied to the skin (0.5 g/10 mm², 3 times a day).

After 30 days of Wubeizi ointment treatment, mice were anesthetized by intraperitoneal injection of 0.1% pentobarbital sodium at 0.1 ml/10 g of body weight and then killed by cervical dislocation, and the keloid tissues were dissociated. The size of the keloid tissues was measured by a vernier caliper as described previously [6].

2.4. Culture of Fibroblasts. The primary cells of the human keloid-derived fibroblasts were dissociated and cultured according to our published procedure [1]. Briefly, after rinsing in D-Hank’s liquid (Shanghai Kang Lang Biological Technology Co., Ltd., Shanghai, China), keloid tissues were cut into small pieces (1 mm³) and placed into a flask. Subsequently, 5 ml of 0.25% trypsin solution (Shanghai Bioleaf Biotech Co., Ltd., Shanghai, China) was added into the flask. After 14 hours of digestion at 4°C, protease was removed, and 5 ml of complete media containing 10% fetal bovine serum (FBS, Shanghai Bioleaf Biotech Co., Ltd.) was added into the flask. Single cell suspension was prepared. Cells were then subcultured in a 25 ml flask and incubated in an incubator (Binder GmbH, Tuttlingen, Germany) at 37°C with 5% CO₂. The generation was passaged every 2–3 days. The 3rd generation cells at logarithmic growth phase were analyzed.

Keloid fibroblasts were divided into four groups; i.e., control group, IGF-1-treated group, IGF-1+Wubeizi ointment-treated group, and Wubeizi ointment-treated group. For the control group, 20 μl DMEM containing 5% FBS was added to the culture medium. For the IGF-1-treated group, 20 μl IGF-1 (Thermo Fisher Scientific, USA) was added. IGF-1 is an agonist of the mTOR signaling pathway. For the IGF-1+Wubeizi ointment-treated group, 20 μl mixture of IGF-1 and Wubeizi ointment was added. For the Wubeizi ointment-treated group, 20 μl of the Wubeizi ointment solution was added. The Wubeizi ointment solution used for in vitro experiments was prepared by dissolving the extract of Wubeizi ointment in water at a concentration of 0.5 mg/ml.

2.5. Immunohistochemistry. Immunocytochemistry was conducted as described previously [6]. Briefly, keloid fragments (5 mm × 5 mm × 5 mm) were fixed in 4% paraformaldehyde at 4°C for 48 h, embedded in paraffin, sectioned at 4 μm thickness by Rotary Paraffin Microtome Slicer paraaffin
embedding machine (Media Cybernetics, USA), and stained with hematoxylin and eosin for routine examination. Subsequently, the keloid sections were incubated with antibodies against p-P13K (1:100, mouse anti-human P13K monoclonal antibody, Santa Cruz, CA, USA), PTEN (1:100, mouse anti-human PTEN (a2b1) monoclonal antibody, Santa Cruz, CA, USA), p-Akt (1:100, mouse anti-human Akt monoclonal antibody, Santa Cruz, CA, USA), or p-mTOR (1:100, mouse anti-human mTOR monoclonal antibody, Santa Cruz, CA, USA). Bound antibodies were visualized using 3,3′-diaminobenzidine (DAB) as a chromogen (ZSGB Bio Co., Ltd, Beijing, China), and the slides were counterstained with hematoxylin. The positive expression of p-P13K, PTEN, p-Akt, and p-mTOR was evaluated in four randomly selected regions indicated the number of apoptotic cells.

2.8. MTT Assay. The proliferation rate of keloid fibroblasts at specific time points (12 h, 24 h, 36 h and 48 h after drug treatment) was measured by the MTT assay. The MTT assay was performed as described previously [1]. Briefly, the cells were seeded in 96-well plates. After drug treatment (5% Wubeizi ointment), 20 μl MTT was added to each well. After incubating for 4 h at 37°C, the liquid was removed, and dimethyl sulfoxide (150 μl/well) was added. After dissolution of the blue-purple formazan, optical density (OD) was measured 1 h later in a microplate reader (BioRad, USA) at a wavelength of 490 nm.

2.9. Flow Cytometric Analysis. The apoptosis of keloid fibroblasts was analyzed by flow cytometry according as described previously [1]. Briefly, 48 h after drug treatment (5% Wubeizi ointment), keloid fibroblasts were collected and rinsed thrice in PBS. 5 μl of Annexin V-FITC was added to 2 × 10^5 cells for 15 min following by 5 μl PI and incubated in dark at 4°C for 5 min. The cells were subjected to flow cytometry (Beckman Coulter, Inc., USA). Dot intensities in both Q2 and Q3 regions indicated the number of apoptotic cells.

2.10. Statistical Analysis. Statistical analysis was done using SPSS version 20.0 (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp.). Data were presented as mean ± S.D. For two variable comparisons, a two independent samples t-test was used. For multiple variable comparisons, data were analyzed by the χ² test or one-way analysis of variance (ANOVA) followed by pairwise q-tests.

3. Results

3.1. The Inhibitory Effect of Wubeizi Ointment on the Size of Keloid Scar. As show in Figure 1, the sizes of keloid tissues dissociated from 5% Wubeizi ointment-treated nude mice washed with PBS, and then incubated with secondary antibody (biotinylated goat anti-rabbit secondary antibody, 1:1000, Berseebio Co., Ltd, Beijing, China) and conjugated to horseradish peroxidase for 1 h at room temperature. The membranes were washed with PBS, and immunoreactivity was visualized on Odyssey infrared fluorescence imager (LI-COR Biosciences, Lincoln, NE, USA). Images were analyzed by using the Image Pro-Plus image analysis system.

| Primer | Sequences (5′-3′) |
|--------|------------------|
| P13KCA-forward | TGATGCTCTCTAGGGCTTT |
| P13KCA-reverse | GTCGTTGFTTCTCCAATTCA |
| PTEN-forward | TGGAAGACCTATAACCCACCA |
| PTEN-reverse | CATACGGGCTTCTGACTGG |
| Akt1-forward | TCTATTGACCTGAGATTGTG |
| Akt1-reverse | CTTAATGTGCCGTCCCTTGT |
| mTOR-forward | ACTGCGTCTTATGACCAACTGA |
| mTOR-reverse | TTTCATGACAACTGGTCTATTG |
| β-Actin-forward | CCTAGAAGCATTTGCAGGTGG |
| β-Actin-reverse | GAGCTACGAGCTGCCTAGC |

Table 1: Primer for real-time PCR.
3.2. The Inhibitory Effect of Wubeizi Ointment on the Size of Keloid Scar.

After 30 days of Wubeizi ointment treatment, mice were sacrificed, and the keloid tissues were disassociated. The size of the keloid tissues was measured by a vernier caliper. Representative pictures are shown (n = 6).

were 252.84 ± 38.57 mm³ (n = 6), which were significantly smaller than the sizes of keloid tissues disassociated from 3% Wubeizi ointment-treated nude mice (463.37 ± 51.82 mm³, n = 6) and control nude mice (785.63 ± 78.24 mm³, n = 6) (P < 0.05).

3.3. The Inhibitory Effect of Wubeizi Ointment on Proliferation and Apoptosis of Keloid Fibroblasts. Results of the MTT assay showed that IGF-1 promoted fibroblast proliferation whilst Wubeizi ointment inhibited fibroblast proliferation (Figure 4(a), P < 0.05). In addition, the inhibitory effect of Wubeizi ointment on fibroblast proliferation could be attenuated by IGF-1 (Figure 4(a)). Results of flow cytometry showed that Wubeizi ointment was able to promote fibroblast apoptosis (control vs. Wubeizi ointment-treated group, 8.20 ± 0.78 vs. 29.82 ± 2.34, n = 24, P < 0.05) (Figure 4(b)). The inhibitory effect of Wubeizi ointment on fibroblast apoptosis could be attenuated by IGF-1 (Wubeizi ointment-treated vs. IGF-1+Wubeizi ointment-treated group, 29.82 ± 2.34 vs. 18.47 ± 1.86, n = 24) (Figure 4(b)).

3.4. The Inhibitory Effect of Wubeizi Ointment on the Phosphorylated Protein and mRNA Levels of PI3K, PTEN, Akt, and mTOR in Keloid Fibroblasts. The results of qPCR showed that, compared to the control group, mRNA levels of PIK3CA, Akt1, and mTOR were significantly increased in keloid fibroblasts from the IGF-1-treated group (Figure 5(a), P < 0.05).

Compared to the control and Wubeizi ointment treated-group, mRNA levels of PIK3CA were significantly increased in keloid fibroblasts from the IGF-1+Wubeizi ointment-treated group and IGF-1-treated group (Figure 5(a), P < 0.05). However, there was no significant difference between the Wubeizi ointment-treated and control group in PI3K mRNA levels in keloid fibroblasts (Figure 5(a), P = 0.418). Compared to the control and IGF-1-treated group, mRNA levels of PTEN were significantly increased in keloid fibroblasts from the IGF-1+Wubeizi ointment-treated group and Wubeizi ointment-treated group (Figure 5(a), P < 0.01). However, there was no significant difference between the IGF-1-treated and control group in the mRNA levels of PTEN in keloid fibroblasts (Figure 5(a), P = 0.9). In contrast, compared to the control group, mRNA levels of Akt1 and mTOR were significantly decreased in keloid fibroblasts from the IGF-1+Wubeizi ointment-treated group and Wubeizi ointment-treated group (Figure 5(a), P < 0.05). The mRNA levels of Akt1 and mTOR in keloid fibroblasts from the IGF-1+Wubeizi ointment-treated group was higher than those in keloid fibroblasts from the Wubeizi ointment-treated group (Figure 5(a), P < 0.05).

The results of western blot showed that, compared to the control group, phosphorylated protein levels of p-PI3K, p-Akt, and p-mTOR were significantly increased in keloid fibroblasts from the IGF-1+Wubeizi ointment-treated group (Figure 5(b), P < 0.05).

Compared to the control and Wubeizi ointment-treated group, protein levels of p-PI3K were significantly increased in keloid fibroblasts from the IGF-1+Wubeizi ointment-treated group and IGF-1-treated group (Figure 5(b), P < 0.05).

These data suggested that Wubeizi ointment could downregulate the mRNA expression levels of Akt1 and mTOR and upregulate PTEN mRNA expression levels in keloid tissues. It also could reduce phosphorylated protein levels of Akt and mTOR in keloid tissues.
However, no significant difference was found between the control and Wubeizi ointment-treated group in the protein levels of p-PI3K in keloid fibroblasts (Figure 5(b), $P > 0.05$). Compared to the control and IGF-1-treated group, protein levels of PTEN were significantly increased in keloid fibroblasts from the IGF-1+Wubeizi ointment-treated group and Wubeizi ointment-treated group (Figure 5(b), $P < 0.05$). No significant difference was found between the control and IGF-1 group in the protein levels of PTEN in keloid fibroblasts (Figure 5(b), $P = 0.364$). In contrast, compared to the control group, protein levels of p-Akt and p-mTOR were significantly decreased in keloid fibroblasts from the IGF-1+Wubeizi ointment-treated group and Wubeizi ointment-treated group (Figure 5(b), $P < 0.05$). The protein levels of p-Akt and p-mTOR in keloid fibroblasts from the IGF-1+Wubeizi ointment-treated group was higher than those in keloid fibroblasts from the Wubeizi ointment-treated group (Figure 5(b), $P < 0.05$).

These data suggest that Wubeizi ointment was able to downregulate the mRNA expression levels of Akt and mTOR and upregulate the mRNA expression levels of PTEN in keloid fibroblasts. It also could reduce phosphorylated protein levels of Akt and mTOR in keloid fibroblasts. These effects of Wubeizi ointment could be attenuated by IGF-1.

4. Discussion

The current study explored if Wubeizi ointment could suppress keloid formation through the modulation of the mTOR signaling pathway. The results showed Wubeizi ointment could reduce the size of keloid morphologically in nude mice and could influence the expression pattern of some key factors involved in the mTOR pathway both in the keloid tissues and in cultured keloid fibroblast cells. While there was upregulation of PTEN and downregulation of p-Akt and p-mTOR, no significant difference in the expression level of p-PI3K was seen.
Keloids are formed due to abnormal cellular proliferation of fibroblasts producing high amounts of collagen and matrix metalloproteinases (MMP). Aberrant accumulation of extracellular matrix collagens, mucins, and glycosaminoglycans because of an imbalance between collagen production and degradation of the extracellular matrix can lead to the elevated production of cytokines and pro-inflammatory responses. Faulty fibroblast regulation resulting in proliferation of fibroblasts and apoptosis inhibition plays an important role in the keloid development and scar formation [7].

Our previous study demonstrated that Wubeizi ointment increased fibroblasts at the S phase thereby greatly reduced dividing fibroblasts in addition to inhibiting the proliferation of keloid-derived fibroblasts in a time- and dose-dependent manner [1]. Moreover, Wubeizi ointment could downregulate the expression of type I and III procollagen in keloid fibroblast, subsequently reducing collagen deposition in the keloid tissue [2]. In support of these findings, the present study demonstrated that Wubeizi ointment reduced the size of the keloid tissue through inhibition of fibroblast proliferation and promotion of fibroblast apoptosis.

It has been demonstrated that the proliferation of keloid fibroblasts could be regulated by various cytokines, such as TGF-β1 [4]. Keloid fibroblast proliferation and transdifferentiation are promoted by TGF-β1 through upregulation of the miR-21 and PTEN/AKT signaling pathway [8]. Keloid fibroblast proliferation and collagen synthesis as well as inhibition of the collagen-degrading activity of MMP are stimulated by TGF-β. Scarring can be reduced in rodents by inhibition of TGF-β signaling proteins [9]. The mTOR signaling pathway plays an important role in the TGF-β1
The mTOR signal pathway includes upstream PI3K, Akt, and PTEN, among which PTEN acts as a negative feedback regulating factor of the mTOR signal pathway [8]. The mTOR gene is closely associated with the occurrence of various tumors, such as glioma, esophageal, and colorectal cancer [13–19]. Pathological characteristics of keloid are very similar to those of benign solid tumor and can invasively grow to surrounding normal tissues [4]. These findings suggest that the mTOR signaling pathway may be important in the process of keloid fibroblast proliferation, and our study provides evidence that genes involved in this process are modulated by Wubeizi ointment.

It was found that inhibition of mTOR can reduce extracellular matrix deposition [20, 21]. In addition, the expression of mTOR and its upstream molecules PI3K and Akt were significantly increased in keloid tissues [3, 4]. Furthermore, application of rapamycin to monoculture keloid fibroblasts could downregulate the expression of cytoplasmic PCNA, cyclin D1, fibronectin, collagen, and alpha-SMA [3]. These data raise the possibility that Wubeizi ointment inhibits the formation of keloid scar through modulation of the mTOR pathway. To confirm the hypothesis, in vitro experiments with cultured keloid fibroblasts and in vivo experiments with nude mice induced with keloids were performed, and the results showed that Wubeizi ointment can...
interfere with the mTOR signaling pathway. We used IGF-1, an agonist of the mTOR signaling pathway [19], to activate the mTOR signaling pathway after adding Wubeizi ointment, and then the proliferation of keloid fibroblasts was detected to test whether the drug efficacy is inhibited. This can confirm whether the mechanism of Wubeizi ointment regulates the mTOR signaling pathway to inhibit the proliferation of keloid fibroblasts. In the in vitro experiment, after the addition of IGF-1, the effect of Wubeizi ointment on inhibiting proliferation of keloid fibroblasts and promoting its apoptosis was diminished. It suggests that the mechanism of Wubeizi ointment inhibiting the proliferation of keloid fibroblasts is related to the regulation of the mTOR signaling pathway. This study demonstrated that Wubeizi ointment inhibited the proliferation of keloid fibroblasts and promoted the apoptosis of keloid fibroblasts, probably through downregulation of Akt and mTOR and upregulation of PTEN.

This study is limited by the fact that it is preliminary in nature, and in-depth mechanism of action of Wubeizi ointment is warranted in future studies.

5. Conclusion

In conclusion, the present study investigated if Wubeizi ointment inhibited the keloid formation through modulation of key molecules of the mTOR pathway including PTEN, PI3K, and Akt. The results of the in vivo and in vitro studies suggested that Wubeizi ointment inhibited the proliferation of keloid fibroblasts and promoted the apoptosis of keloid fibroblasts, probably through downregulation of Akt and mTOR and upregulation of PTEN. These findings may contribute to a better understanding of the mechanism of Wubeizi ointment for treating keloid and provide a theoretical basis for its clinical application.
Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

The study protocol for using human tissue samples and for performing animal experiments was, respectively, approved by the Ethics Committees of the Xuzhou Hospital affiliated to Nanjing University of Traditional Chinese Medicine (approval number: 201804-02) and Experimental Animal Ethics Committee of Nanjing University of Traditional Chinese Medicine (approval number: EAEC-2018051303). Written informed consent was obtained from all the patients prior to commencement of this study.

Disclosure

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Zhiming Tang, Yi Cao, and Jicun Ding contributed equally to this work.

Acknowledgments

The study supported by the National Natural Science Foundation of China (81673976) and Clinical Chinese Medicine Plateau Discipline Construction Project of Shanghai Pudong New Area Health Committee (PDZY-2018-0604).

References

[1] J. Ding, Z. Tang, X. Zhai, X. Chen, J. Li, and C. Zhang, "The effects of Wubeizi ointment on the proliferation of keloid-derived fibroblasts," Cell Biochemistry and Biophysics, vol. 71, no. 1, pp. 431–435, 2015.

[2] X.-X. Zhai, J.-C. Ding, Z.-M. Tang, J.-G. Li, X.-H. Chen, and C.-X. Zhang, "Effect of Wubeizi ointment aqueous solution on the expression of type I and III procollagen genes in keloid fibroblasts," Experimental and Therapeutic Medicine, vol. 13, no. 2, pp. 503–506, 2017.

[3] C. T. Ong, Y. T. Khoo, A. Mukhopadhyay et al., "mTOR as a potential therapeutic target for treatment of keloids and excessive scars," Experimental Dermatology, vol. 16, no. 5, pp. 394–404, 2007.

[4] X.-X. Zhai, Z.-M. Tang, J.-C. Ding, and X.-L. Lu, "Expression of TGF-β1/mTOR signaling pathway in pathological scar fibroblasts," Molecular Medicine Reports, vol. 15, no. 6, pp. 3467–3472, 2017.

[5] C. Philandrianos, D. Gonnelli, L. Andrac-Meyer, M. Bruno, G. Magalon, and S. Mordon, Eds., Establishment of a Keloid Model by Transplanting Human Keloid onto the Backs of Nude Mice, Annales de chirurgie plastique et esthetique, 2014.

[6] M. Barara, R. Chander, and V. Mendiratta, "Cryotherapy in treatment of keloids: evaluation of factors affecting treatment outcome," Journal of Cutaneous and Aesthetic Surgery, vol. 5, no. 3, pp. 185–189, 2012.

[7] T. Matsuoka and M. Yashiro, "The role of PI3K/Akt/mTOR signaling in gastric carcinoma," Cancers, vol. 6, no. 3, pp. 1441–1463, 2014.

[8] A. Gomez-Pinillos and A. C. Ferrari, "mTOR signaling pathway and mTOR inhibitors in cancer therapy," Hematology/Oncology Clinics of North America, vol. 26, no. 3, pp. 483–505, 2012.

[9] A. J. van den Bogaerd, V. C. van der Veen, P. P. M. van Zuijlen et al., "Collagen cross-linking by adipose-derived mesenchymal stromal cells and scar-derived mesenchymal cells: are mesenchymal stromal cells involved in scar formation?," Wound Repair and Regeneration, vol. 17, no. 4, pp. 548–558, 2009.

[10] S. Xavier, T. Niranjian, S. Krick et al., "TβRII independently activates Smad- and CD2AP-dependent pathways in podocytes," Journal of the American Society of Nephrology, vol. 20, no. 10, pp. 2127–2137, 2009.

[11] K. Cheng and M. Hao, "Mammalian target of rapamycin (mTOR) regulates transforming growth factor-β1 (TGF-β1)-induced epithelial-mesenchymal transition via decreased pyruvate kinase M2 (PKM2) expression in cervical cancer cells," Medical Science Monitor, vol. 23, pp. 2017–2028, 2017.

[12] S. Viel, A. Marçais, F. S.-F. Guimaraes et al., "TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway," Science Signaling, vol. 9, no. 415, article ra19, 2016.

[13] L. S. Steelman, W. H. Chappell, S. L. Abrams et al., "Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging," Aging, vol. 3, no. 3, pp. 192–222, 2011.

[14] J.-F. Teng, D.-L. Qin, Q.-B. Mei et al., "Polyphillin VI, a saponin from Trillium tschonoskii Maxim. induces apoptotic and autophagic cell death via the ROS triggered mTOR signaling pathway in non-small cell lung cancer," Pharmacological Research, vol. 147, article 104396, 2019.

[15] Y. Wang, C. Wang, H. Xiao et al., "Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer," Cancer Medicine, vol. 6, no. 1, pp. 45–53, 2017.

[16] A. E. M. Marques, S. T. Elias, A. L. Porporatti et al., "mTOR pathway protein immunexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis," Journal of Oral Pathology & Medicine, vol. 45, no. 5, pp. 319–328, 2016.

[17] T. Tian, X. Li, and J. Zhang, "mTOR signaling in cancer and mtor inhibitors in solid tumor targeting therapy," International Journal of Molecular Sciences, vol. 20, no. 3, pp. 755, 2019.

[18] J. Aldaregia, A. Odriozola, A. Matheu, and I. Garcia, "Targeting mtor as a therapeutic approach in medulloblastoma," International Journal of Molecular Sciences, vol. 19, no. 7, pp. 1838, 2018.

[19] M. Ghidini, F. Petrelli, A. Ghidini et al., "Clinical development of mTor inhibitors for renal cancer," Expert Opinion on Investigational Drugs, vol. 26, no. 11, pp. 1229–1237, 2017.
[20] L. P. Huang, Z. Mao, L. Zhang, X. X. Liu, C. Huang, and Z. S. Jia, “Screening of differentially expressed genes in pathological scar tissues using expression microarray,” Genetics and Molecular Research, vol. 14, no. 3, pp. 10743–10751, 2015.

[21] M. Goder, R. Kornhaber, D. Bordoni, E. Winkler, J. Haik, and A. Tessone, “Cutaneous basal cell carcinoma arising within a keloid scar: a case report,” OncoTargets and Therapy, vol. 9, pp. 4793–4796, 2016.